title: INFECTIOUS KERATITIS-ASSOCIATED ENDOPHTHALMITIS: A 14-Year Study.
abstract: OBJECTIVE
  To describe the demographics, characteristics, management, and outcomes of eyes with endophthalmitis related to infectious keratitis.
  
  
  METHODS
  Retrospective chart review of all patients treated for infectious keratitis-associated infectious endophthalmitis between 2001 and 2014 at University Hospital, Rutgers New Jersey Medical School.
  
  
  RESULTS
  Thirty-eight cases with infectious keratitis-associated infectious endophthalmitis were identified (21 men [55%], mean age: 66.2 ± 20.7 years), with average time from the beginning of ulcer symptoms to endophthalmitis of 11.0 days. Associated systemic conditions (diabetes, HIV, immunosuppressive therapy, cirrhosis, or dementia) were present in 57.9%; 60.5% had previous intraocular surgery. Etiology showed gram-positive bacteria in 14 cases (36.9%), gram-negative bacteria in 7 (18.4%), fungi in 4 (10.5%), and no growth/unknown in 12 (31.6%). Nineteen cases (50%) presented with no light perception and were primarily enucleated. The remaining 19 eyes each received intravitreal antibiotics (mean: 1.5 injections); 8 (42.0%) underwent pars plans vitrectomy with vitreous biopsy, whereas 5 (26.3%) received emergency corneal transplantation. Final visual acuity was no light perception in 6 eyes (3 secondarily enucleated), light perception in 2, hand motion in 7, counting fingers in 2, and ≥20/50 in 2.
  
  
  CONCLUSIONS
  Our study of 38 eyes with infectious keratitis-associated infectious endophthalmitis revealed generally poor visual outcomes and a high rate of systemic conditions and previous intraocular surgery.
authors.affiliation: Department of Ophthalmology, The Institute of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey.
authors.forename: Mehrdad
authors.initials: M
authors.lastname: Malihi
authors.forename: Xintong
authors.initials: X
authors.lastname: Li
authors.forename: Shriji
authors.initials: S
authors.lastname: Patel
authors.forename: Thomas
authors.initials: T
authors.lastname: Eck
authors.forename: David S
authors.initials: DS
authors.lastname: Chu
authors.forename: Marco A
authors.initials: MA
authors.lastname: Zarbin
authors.forename: Neelakshi
authors.initials: N
authors.lastname: Bhagat
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D009877:Endophthalmitis / Q000209:etiology / Q000382:microbiology / Q000628:therapy; D015818:Eye Infections, Bacterial / Q000150:complications* / Q000382:microbiology / Q000628:therapy; D015821:Eye Infections, Fungal / Q000150:complications* / Q000382:microbiology / Q000628:therapy; D005260:Female; D006801:Humans; D007634:Keratitis / Q000150:complications / Q000382:microbiology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D013508:Ophthalmologic Surgical Procedures; D012189:Retrospective Studies; D012307:Risk Factors; D014792:Visual Acuity
chemical_list: D000900:Anti-Bacterial Agents